S&P 500   3,959.31 (-0.11%)
DOW   33,702.72 (-0.23%)
QQQ   283.23 (-0.22%)
AAPL   142.06 (-0.41%)
MSFT   244.98 (-0.98%)
META   115.56 (+0.20%)
GOOGL   93.73 (+0.02%)
AMZN   89.40 (-1.05%)
TSLA   178.02 (+2.64%)
NVDA   172.96 (+0.74%)
NIO   13.06 (-2.61%)
BABA   92.97 (-1.27%)
AMD   69.35 (-1.59%)
T   19.24 (+0.63%)
MU   55.32 (+0.22%)
CGC   2.99 (-3.24%)
F   13.27 (+1.14%)
GE   82.31 (-1.58%)
DIS   93.59 (+1.12%)
AMC   6.02 (-0.82%)
PYPL   74.16 (-0.08%)
PFE   51.82 (+0.08%)
NFLX   324.02 (+4.43%)
S&P 500   3,959.31 (-0.11%)
DOW   33,702.72 (-0.23%)
QQQ   283.23 (-0.22%)
AAPL   142.06 (-0.41%)
MSFT   244.98 (-0.98%)
META   115.56 (+0.20%)
GOOGL   93.73 (+0.02%)
AMZN   89.40 (-1.05%)
TSLA   178.02 (+2.64%)
NVDA   172.96 (+0.74%)
NIO   13.06 (-2.61%)
BABA   92.97 (-1.27%)
AMD   69.35 (-1.59%)
T   19.24 (+0.63%)
MU   55.32 (+0.22%)
CGC   2.99 (-3.24%)
F   13.27 (+1.14%)
GE   82.31 (-1.58%)
DIS   93.59 (+1.12%)
AMC   6.02 (-0.82%)
PYPL   74.16 (-0.08%)
PFE   51.82 (+0.08%)
NFLX   324.02 (+4.43%)
S&P 500   3,959.31 (-0.11%)
DOW   33,702.72 (-0.23%)
QQQ   283.23 (-0.22%)
AAPL   142.06 (-0.41%)
MSFT   244.98 (-0.98%)
META   115.56 (+0.20%)
GOOGL   93.73 (+0.02%)
AMZN   89.40 (-1.05%)
TSLA   178.02 (+2.64%)
NVDA   172.96 (+0.74%)
NIO   13.06 (-2.61%)
BABA   92.97 (-1.27%)
AMD   69.35 (-1.59%)
T   19.24 (+0.63%)
MU   55.32 (+0.22%)
CGC   2.99 (-3.24%)
F   13.27 (+1.14%)
GE   82.31 (-1.58%)
DIS   93.59 (+1.12%)
AMC   6.02 (-0.82%)
PYPL   74.16 (-0.08%)
PFE   51.82 (+0.08%)
NFLX   324.02 (+4.43%)
S&P 500   3,959.31 (-0.11%)
DOW   33,702.72 (-0.23%)
QQQ   283.23 (-0.22%)
AAPL   142.06 (-0.41%)
MSFT   244.98 (-0.98%)
META   115.56 (+0.20%)
GOOGL   93.73 (+0.02%)
AMZN   89.40 (-1.05%)
TSLA   178.02 (+2.64%)
NVDA   172.96 (+0.74%)
NIO   13.06 (-2.61%)
BABA   92.97 (-1.27%)
AMD   69.35 (-1.59%)
T   19.24 (+0.63%)
MU   55.32 (+0.22%)
CGC   2.99 (-3.24%)
F   13.27 (+1.14%)
GE   82.31 (-1.58%)
DIS   93.59 (+1.12%)
AMC   6.02 (-0.82%)
PYPL   74.16 (-0.08%)
PFE   51.82 (+0.08%)
NFLX   324.02 (+4.43%)
NASDAQ:CPRX

Catalyst Pharmaceuticals - CPRX Stock Forecast, Price & News

$16.70
-0.10 (-0.60%)
(As of 12/9/2022 10:16 AM ET)
Add
Compare
Today's Range
$16.46
$16.96
50-Day Range
$12.25
$17.51
52-Week Range
$5.24
$18.39
Volume
4,015 shs
Average Volume
2.72 million shs
Market Capitalization
$1.74 billion
P/E Ratio
27.38
Dividend Yield
N/A
Price Target
$17.13

Catalyst Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.75 Rating Score
Upside/​Downside
1.9% Upside
$17.13 Price Target
Short Interest
Healthy
6.84% of Float Sold Short
Dividend Strength
N/A
Sustainability
-2.01
Upright™ Environmental Score
News Sentiment
0.64mentions of Catalyst Pharmaceuticals in the last 14 days
Based on 5 Articles This Week
Insider Trading
Selling Shares
$21.21 M Sold Last Quarter
Proj. Earnings Growth
19.18%
From $0.73 to $0.87 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.53 out of 5 stars

Medical Sector

147th out of 1,022 stocks

Pharmaceutical Preparations Industry

56th out of 499 stocks

CPRX stock logo

About Catalyst Pharmaceuticals (NASDAQ:CPRX) Stock

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company also develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis, and spinal muscular atrophy type 3, as well as to treat hereditary neuropathy with liability to pressure palsies. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.

Receive CPRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Catalyst Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

CPRX Stock News Headlines

Is Mid-Cap Neurocrine Biosciences A Buy After Blowout Q3 Report? (CPRX)
Neurocrine Biosciences trended higher with the broad market Thursday, coming within a penny of Tuesday’s high of $125.99. It is forming a bullish channel.
VP At This Health Care Company Sells $946K of Stock
Massive Insider Trade At Catalyst Pharmaceuticals
Catalyst Pharmaceuticals (NASDAQ: CPRX)
5 Stocks to Bet on in an Innovation-Driven Drug Industry
See More Headlines
Receive CPRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Catalyst Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

CPRX Company Calendar

Last Earnings
11/09/2021
Today
12/09/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
3/15/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CPRX
Employees
76
Year Founded
2002

Price Target and Rating

Average Stock Price Forecast
$17.13
High Stock Price Forecast
$18.00
Low Stock Price Forecast
$15.50
Forecasted Upside/Downside
+2.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
4 Analysts

Profitability

Net Income
$39.48 million
Pretax Margin
44.08%

Debt

Sales & Book Value

Annual Sales
$140.83 million
Cash Flow
$0.38 per share
Book Value
$2.01 per share

Miscellaneous

Free Float
89,397,000
Market Cap
$1.74 billion
Optionable
Optionable
Beta
1.25

Social Links


Key Executives

  • Mr. Patrick J. McEnanyMr. Patrick J. McEnany (Age 75)
    Co-Founder, Chairman, Pres & CEO
    Comp: $1.05M
  • Ms. Alicia Grande C.M.A.Ms. Alicia Grande C.M.A. (Age 51)
    CPA, CMA, CPA, Chief Accounting Officer, VP, Treasurer & CFO
    Comp: $617.94k
  • Dr. Steven R. Miller Ph.D.Dr. Steven R. Miller Ph.D. (Age 60)
    COO & Chief Scientific Officer
    Comp: $745.71k
  • Dr. Gary Ingenito M.D.Dr. Gary Ingenito M.D. (Age 66)
    Ph.D., Chief Medical & Regulatory Officer
    Comp: $706.86k
  • Dr. Preethi Sundaram Ph.D. (Age 46)
    Chief Strategy Officer
    Comp: $511.25k
  • Ms. Mary Coleman
    VP & Head of Investor Relations
  • Mr. Brian Elsbernd J.D. (Age 58)
    Chief Compliance Officer & Chief Legal Officer
  • Mr. Pete Curry Sr.
    VP of Sales
  • Mr. Jeffrey Del Carmen (Age 51)
    Chief Commercial Officer
  • Mr. Philip B. Schwartz (Age 67)
    Corp. Sec.













CPRX Stock - Frequently Asked Questions

Should I buy or sell Catalyst Pharmaceuticals stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Catalyst Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CPRX shares.
View CPRX analyst ratings
or view top-rated stocks.

What is Catalyst Pharmaceuticals' stock price forecast for 2023?

4 brokers have issued 12 month target prices for Catalyst Pharmaceuticals' shares. Their CPRX share price forecasts range from $15.50 to $18.00. On average, they expect the company's stock price to reach $17.13 in the next year. This suggests a possible upside of 1.9% from the stock's current price.
View analysts price targets for CPRX
or view top-rated stocks among Wall Street analysts.

How have CPRX shares performed in 2022?

Catalyst Pharmaceuticals' stock was trading at $6.77 at the beginning of 2022. Since then, CPRX stock has increased by 148.2% and is now trading at $16.80.
View the best growth stocks for 2022 here
.

Are investors shorting Catalyst Pharmaceuticals?

Catalyst Pharmaceuticals saw a decline in short interest in the month of November. As of November 15th, there was short interest totaling 6,670,000 shares, a decline of 17.2% from the October 31st total of 8,060,000 shares. Based on an average trading volume of 3,260,000 shares, the short-interest ratio is presently 2.0 days. Currently, 6.8% of the company's stock are sold short.
View Catalyst Pharmaceuticals' Short Interest
.

When is Catalyst Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 15th 2023.
View our CPRX earnings forecast
.

How were Catalyst Pharmaceuticals' earnings last quarter?

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) issued its quarterly earnings data on Tuesday, November, 9th. The biopharmaceutical company reported $0.10 earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of $0.10. The biopharmaceutical company earned $35.95 million during the quarter, compared to analyst estimates of $34.47 million. Catalyst Pharmaceuticals had a net margin of 34.90% and a trailing twelve-month return on equity of 28.53%. During the same period in the prior year, the business posted $0.11 EPS.

What guidance has Catalyst Pharmaceuticals issued on next quarter's earnings?

Catalyst Pharmaceuticals updated its FY 2022 earnings guidance on Friday, December, 9th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $205.00 million-$210.00 million, compared to the consensus revenue estimate of $205.03 million.

What other stocks do shareholders of Catalyst Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Catalyst Pharmaceuticals investors own include Novavax (NVAX), Sorrento Therapeutics (SRNE), Amarin (AMRN), Inovio Pharmaceuticals (INO), Corbus Pharmaceuticals (CRBP), Micron Technology (MU), Verastem (VSTM), Exelixis (EXEL), Rigel Pharmaceuticals (RIGL) and TherapeuticsMD (TXMD).

What is Catalyst Pharmaceuticals' stock symbol?

Catalyst Pharmaceuticals trades on the NASDAQ under the ticker symbol "CPRX."

Who are Catalyst Pharmaceuticals' major shareholders?

Catalyst Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (14.67%), State Street Corp (7.26%), Vanguard Group Inc. (5.90%), LSV Asset Management (3.30%), Renaissance Technologies LLC (2.14%) and Dimensional Fund Advisors LP (2.08%). Insiders that own company stock include Alicia Grande, Charles B O'keeffe, David S Tierney, Donald A Denkhaus, Gary Ingenito, Patrick J Mcenany, Philip H Coelho, Preethi Sundaram and Steve Miller.
View institutional ownership trends
.

How do I buy shares of Catalyst Pharmaceuticals?

Shares of CPRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Catalyst Pharmaceuticals' stock price today?

One share of CPRX stock can currently be purchased for approximately $16.80.

How much money does Catalyst Pharmaceuticals make?

Catalyst Pharmaceuticals (NASDAQ:CPRX) has a market capitalization of $1.75 billion and generates $140.83 million in revenue each year. The biopharmaceutical company earns $39.48 million in net income (profit) each year or $0.61 on an earnings per share basis.

How can I contact Catalyst Pharmaceuticals?

Catalyst Pharmaceuticals' mailing address is 355 ALHAMBRA CIRCLE SUITE 1250, CORAL GABLES FL, 33134. The official website for the company is www.catalystpharma.com. The biopharmaceutical company can be reached via phone at (305) 420-3200, via email at bkorb@troutgroup.com, or via fax at 305-529-0933.

This page (NASDAQ:CPRX) was last updated on 12/9/2022 by MarketBeat.com Staff